Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

What is the clinically relevant change on the ADAS-Cog?

Schrag A, Schott JM; Alzheimer's Disease Neuroimaging Initiative..

J Neurol Neurosurg Psychiatry. 2012 Feb;83(2):171-3. doi: 10.1136/jnnp-2011-300881.

PMID:
22019547
2.

Long-term changes in ADAS-cog: what is clinically relevant for disease modifying trials in Alzheimer?

Vellas B, Andrieu S, Cantet C, Dartigues JF, Gauthier S.

J Nutr Health Aging. 2007 Jul-Aug;11(4):338-41.

PMID:
17653494
3.

Psychometric evaluation of ADAS-Cog and NTB for measuring drug response.

Karin A, Hannesdottir K, Jaeger J, Annas P, Segerdahl M, Karlsson P, Sjögren N, von Rosen T, Miller F.

Acta Neurol Scand. 2014 Feb;129(2):114-22. doi: 10.1111/ane.12153.

PMID:
23763450
4.
5.

The ADAS-Cog revisited: novel composite scales based on ADAS-Cog to improve efficiency in MCI and early AD trials.

Raghavan N, Samtani MN, Farnum M, Yang E, Novak G, Grundman M, Narayan V, DiBernardo A; Alzheimer’s Disease Neuroimaging Initiative..

Alzheimers Dement. 2013 Feb;9(1 Suppl):S21-31. doi: 10.1016/j.jalz.2012.05.2187.

6.

Predictors of placebo group decline in the Alzheimer's disease Assessment Scale-cognitive subscale (ADAS-Cog) in 24 week clinical trials of Alzheimer's disease.

Irizarry MC, Webb DJ, Bains C, Barrett SJ, Lai RY, Laroche JP, Hosford D, Maher-Edwards G, Weil JG.

J Alzheimers Dis. 2008 Jul;14(3):301-11.

PMID:
18599956
7.

Predictive value of 6-month decline in ADAS-cog for survival without severe Alzheimer's disease.

Helmer C, Andrieu S, Pérès K, Orgogozo JM, Vellas B, Dartigues JF; REAL.fr Group..

Dement Geriatr Cogn Disord. 2007;23(3):168-74.

PMID:
17215578
8.
11.

Galantamine for Alzheimer's disease.

Olin J, Schneider L.

Cochrane Database Syst Rev. 2001;(4):CD001747. Review. Update in: Cochrane Database Syst Rev. 2002;(3):CD001747.

PMID:
11687119
12.

Galantamine for Alzheimer's disease and mild cognitive impairment.

Loy C, Schneider L.

Cochrane Database Syst Rev. 2006 Jan 25;(1):CD001747. Review.

PMID:
16437436
13.

Galantamine for Alzheimer's disease.

Olin J, Schneider L.

Cochrane Database Syst Rev. 2002;(3):CD001747. Review. Update in: Cochrane Database Syst Rev. 2004;(4):CD001747.

PMID:
12137632
14.

[Diagnostic value and functional correlations of the ADAS-Cog scale in Alzheimer's disease: data on NORMACODEM project].

Monllau A, Pena-Casanova J, Blesa R, Aguilar M, Bohm P, Sol JM, Hernandez G.

Neurologia. 2007 Oct;22(8):493-501. Spanish.

PMID:
17602338
15.

Adding delayed recall to the Alzheimer Disease Assessment Scale is useful in studies of mild cognitive impairment but not Alzheimer disease.

Sano M, Raman R, Emond J, Thomas RG, Petersen R, Schneider LS, Aisen PS.

Alzheimer Dis Assoc Disord. 2011 Apr-Jun;25(2):122-7. doi: 10.1097/WAD.0b013e3181f883b7.

16.

Carotid intima-media thickness as a predictor of response to cholinesterase inhibitors in Alzheimer's disease: an open-label trial.

Modrego PJ, Rios C, Pérez Trullen JM, García-Gómara MJ, Errea JM.

CNS Drugs. 2009;23(3):253-60. doi: 10.2165/00023210-200923030-00006.

PMID:
19320533
17.

Comparison of the utility of everyday memory test and the Alzheimer's Disease Assessment Scale-Cognitive part for evaluation of mild cognitive impairment and very mild Alzheimer's disease.

Adachi H, Shinagawa S, Komori K, Toyota Y, Mori T, Matsumoto T, Sonobe N, Kashibayashi T, Ishikawa T, Fukuhara R, Ikeda M.

Psychiatry Clin Neurosci. 2013 Apr;67(3):148-53. doi: 10.1111/pcn.12034.

18.

The Alzheimer's Disease Assessment Scale: patterns and predictors of baseline cognitive performance in multicenter Alzheimer's disease trials.

Doraiswamy PM, Bieber F, Kaiser L, Krishnan KR, Reuning-Scherer J, Gulanski B.

Neurology. 1997 Jun;48(6):1511-7.

PMID:
9191757
19.

[Is it pseudo-dementia? The validation of the Adas-Cog questionnaire in Hungary].

Drótos G, Pákáski M, Papp E, Kálmán J.

Psychiatr Hung. 2012;27(2):82-91. Hungarian.

PMID:
22700619
20.

Detecting treatment effects with combinations of the ADAS-cog items in patients with mild and moderate Alzheimer's disease.

Ihl R, Ferris S, Robert P, Winblad B, Gauthier S, Tennigkeit F.

Int J Geriatr Psychiatry. 2012 Jan;27(1):15-21. doi: 10.1002/gps.2679.

PMID:
21384431
Items per page

Supplemental Content

Support Center